The Tacrolimus Concentration/Dose Ratio Does Not Predict Early Complications After Kidney Transplantation

Early-on post kidney transplantation, there is a high risk of graft rejection and opportunistic viral infections. A low tacrolimus concentration/dose (C/D) ratio as a surrogate marker of fast tacrolimus metabolism has been established for risk stratification 3 months post-transplantation (M3). However, many adverse events occurring earlier might be missed, and stratification at 1 month post-transplantation (M1) has not been investigated. We retrospectively analyzed case data from 589 patients who had undergone kidney transplantation between 2011 and 2021 at three German transplant centers. Tacrolimus metabolism was estimated by use of the C/D ratio at M1, M3, M6, and M12. C/D ratios increased substantially during the year, particularly between M1 and M3. Many viral infections and most graft rejections occurred before M3. Neither at M1 nor at M3 was a low C/D ratio associated with susceptibility to BKV viremia or BKV nephritis. A low C/D ratio at M1 could not predict acute graft rejections or impaired kidney function, whereas at M3 it was significantly associated with subsequent rejections and impairment of kidney function. In summary, most rejections occur before M3, but a low C/D ratio at M1 does not identify patients at risk, limiting the predictive utility of this stratification approach. Graphical Abstract

[1]  B. Suwelack,et al.  Increased renal function decline in fast metabolizers using extended-release tacrolimus after kidney transplantation , 2021, Scientific reports.

[2]  P. Griffiths,et al.  Pathogenesis of human cytomegalovirus in the immunocompromised host , 2021, Nature Reviews Microbiology.

[3]  K. Budde,et al.  Effect of Concentration/Dose Ratio in De Novo Kidney Transplant Recipients Receiving LCP-Tacrolimus or Immediate-Release Tacrolimus: Post Hoc Analysis of a Phase 3 Clinical Trial , 2020, Annals of transplantation.

[4]  L. Rostaing,et al.  The TOMATO Study (Tacrolimus Metabolization in Kidney Transplantation): Impact of the Concentration–Dose Ratio on Death-censored Graft Survival , 2020, Transplantation.

[5]  M. Stegall,et al.  The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell– and antibody‐mediated rejection , 2020, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[6]  A. Pathak,et al.  Incidence, clinical profile, and risk factors for serious bacterial infections in children hospitalized with fever in Ujjain, India , 2019, BMC Infectious Diseases.

[7]  Reuter,et al.  Fast Tac Metabolizers at Risk—It is Time for a C/D Ratio Calculation , 2019, Journal of clinical medicine.

[8]  D. Roelen,et al.  A Randomized Controlled Clinical Trial Comparing Belatacept With Tacrolimus After De Novo Kidney Transplantation , 2017, Transplantation.

[9]  Kevin C. Eddinger,et al.  Belatacept Compared With Tacrolimus for Kidney Transplantation: A Propensity Score Matched Cohort Study , 2017, Transplantation.

[10]  A. Åsberg,et al.  High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal Transplantation , 2017, Transplantation.

[11]  H. Pavenstädt,et al.  Influence of tacrolimus metabolism rate on BKV infection after kidney transplantation , 2016, Scientific Reports.

[12]  L. Rostaing,et al.  Long‐Term Outcomes in Belatacept‐ Versus Cyclosporine‐Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT‐EXT, a Phase III Randomized Study , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  H. Gerth,et al.  The Tacrolimus Metabolism Rate Influences Renal Function after Kidney Transplantation , 2014, PloS one.

[14]  J. Azzi,et al.  Calcineurin Inhibitors: 40 Years Later, Can’t Live Without … , 2013, The Journal of Immunology.

[15]  E. Cordero,et al.  Cytomegalovirus disease in kidney transplant recipients: incidence, clinical profile, and risk factors. , 2012, Transplantation proceedings.

[16]  A. Matas,et al.  Understanding the Causes of Kidney Transplant Failure: The Dominant Role of Antibody‐Mediated Rejection and Nonadherence , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[17]  A. Bello,et al.  Systematic Review: Kidney Transplantation Compared With Dialysis in Clinically Relevant Outcomes , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[18]  J. Campistol,et al.  A Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study) , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[19]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[20]  Aaron Dall,et al.  BK virus nephritis after renal transplantation. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[21]  P. Halloran,et al.  Reduced exposure to calcineurin inhibitors in renal transplantation. , 2007, The New England journal of medicine.

[22]  P. Beaune,et al.  Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[23]  J. Sellarésa,et al.  Understanding the Causes of Kidney Transplant Failure : The Dominant Role of Antibody-Mediated Rejection and Nonadherence , 2011 .

[24]  K. Iwasaki Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. , 2007, Drug metabolism and pharmacokinetics.